SCICLONE PHARMACEUTICALS INC - FORM 10-K - EX-32.1 - SECTION 1350 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER - March 31, 2011

Attached files

file filename
10-K - FORM 10-K - SCICLONE PHARMACEUTICALS INCd10k.htm
EX-10.29 - AMENDMENT NO. 1 TO MANUFACTURING AND SUPPLY AGREEMENT - SCICLONE PHARMACEUTICALS INCdex1029.htm
EX-10.28 - ASSIGNMENT AND PURCHASE OF INTELLECTUAL PROPERTY RIGHTS AGREEMENT - SCICLONE PHARMACEUTICALS INCdex1028.htm
EX-10.34 - AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT - DR. FRIEDHELM BLOBEL - SCICLONE PHARMACEUTICALS INCdex1034.htm
EX-10.30 - EXECUTIVE SEVERANCE AGREEMENT - GARY TITUS - SCICLONE PHARMACEUTICALS INCdex1030.htm
EX-10.32 - EXECUTIVE SEVERANCE AGREEMENT - ISRAEL RIOS, M.D. - SCICLONE PHARMACEUTICALS INCdex1032.htm
EX-10.31 - EXECUTIVE SEVERANCE AGREEMENT - HANS P. SCHMID - SCICLONE PHARMACEUTICALS INCdex1031.htm
EX-32.2 - SECTION 1350 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER - SCICLONE PHARMACEUTICALS INCdex322.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - SCICLONE PHARMACEUTICALS INCdex231.htm
EX-21.1 - SUBSIDIARIES OF REGISTRANT - SCICLONE PHARMACEUTICALS INCdex211.htm
EX-31.1 - RULE 13A-14(A) CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER - SCICLONE PHARMACEUTICALS INCdex311.htm
EX-31.2 - RULE 13A-14(A) CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER - SCICLONE PHARMACEUTICALS INCdex312.htm
EX-10.35 - AMENDMENT NO. 1 TO CHANGE OF CONTROL AGREEMENT - GARY S. TITUS - SCICLONE PHARMACEUTICALS INCdex1035.htm
EX-10.36 - AMENDMENT NO. 1 TO CHANGE OF CONTROL AGREEMENT - HANS P. SCHMID - SCICLONE PHARMACEUTICALS INCdex1036.htm
EX-10.37 - AMENDMENT NO. 1 TO CHANGE OF CONTROL AGREEMENT - ISRAEL RIOS, M.D. - SCICLONE PHARMACEUTICALS INCdex1037.htm
EX-10.33 - AMENDMENT NO. 2 TO CHANGE OF CONTROL AGREEMENT - DR. FRIEDHELM BLOBEL - SCICLONE PHARMACEUTICALS INCdex1033.htm

EXHIBIT 32.1

SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Friedhelm Blobel, Chief Executive Officer of SciClone Pharmaceuticals, Inc. (the “Registrant”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

 

(1) the Annual Report on Form 10-K of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

Date: March 31, 2011

     /S/    FRIEDHELM BLOBEL, PH.D.        
   

Friedhelm Blobel, Ph.D.

Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to SciClone Pharmaceuticals, Inc. and will be retained by SciClone Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

SCICLONE PHARMACEUTICALS INC Reports